HarborPath Collaborates with Quest Diagnostics to Provide Hepatitis C Resistance Testing for Uninsured Patients
Charlotte, NC, July 2016 – HarborPath, an organization which provides a single point of access to HIV/AIDS and hepatitis C medications through its patient assistance program, today announced a collaborations with Quest Diagnostics to provide free hepatitis C resistance testing for eligible uninsured individuals. The U.S. Food and Drug Administrations (FDA) recommends resistnace testing prior to treatment with Zepatier (elbasvir and grazoprevir), manufactured by Merck & Co., to determine dosage regimen and duration.
“Our collaboration with Quest marks another milestone for HarborPath as we continue to provide medications and resources for uninsured individuals living with HIV/AIDS and hepatitis C who otherwise may be unable to afford their medicadtions and diagnostic testing," said Ken Trogdon, Jr., President of HarborPath. "HarborPath is working with clinics and healthcare facilities in 16 states where there is a high rate of infection. We look forward to adding to our list of partners so we can reach more uninsured individuals in need."
There are two easy ways to get patients the assistance they need.
1. Visit the HarborPath Website and follow the instructions to process a patient through the Quest Diagnostics patient assistance programs
2. Visit QuestDiagnostics.com to access the Quest Diagnostics patient assistance web page and enrollment form to enroll a patient.
"Testing is an important step in the treatment process and we are pleased to partner with HarborPath to offer the hepatitis C resistance test to help healthcare professionals prescribe the most effective treatment regimen for their patients living with hepatitis C," said Jacquie Vealey, Executive Director, Infectious Disease Solutions, Quest Diagnostics.
HarborPath is a non-profit organization that provides access to life-saving medications for uninsured people living with chronic illnesses free of charge. Through an online portal, healthcare professionals can apply for multiple medications donated by pharmaceutical partners on behalf of their uninsured patients living with HIV/AIDS and hepatitis C through a single application. Eligibility status is deterined immediately, and the HarborPath mail order pharmacy ships medications within 48 hours of program approval. For more information, visit www.harborpath.org.
Mike Beyer Sam Brown Inc. PR for HarborPath
Ken Trogdon, Jr.